Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $10.7143.

PSNL has been the topic of a number of recent analyst reports. Needham & Company LLC lifted their price target on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Lake Street Capital reiterated a “buy” rating and set a $11.00 target price on shares of Personalis in a research note on Wednesday, November 5th. Guggenheim boosted their price target on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley raised their price objective on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Personalis in a research report on Friday, January 9th.

Insider Activity at Personalis

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 134,481 shares of company stock valued at $1,397,564. 3.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Kennedy Capital Management LLC raised its stake in Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after acquiring an additional 1,281,695 shares during the period. Aberdeen Group plc raised its position in shares of Personalis by 36.1% in the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after purchasing an additional 861,948 shares during the period. Geode Capital Management LLC raised its position in shares of Personalis by 165.6% in the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after purchasing an additional 851,422 shares during the period. ARK Investment Management LLC lifted its stake in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares in the last quarter. Finally, Blue Water Life Science Advisors LP boosted its holdings in Personalis by 42.6% in the 2nd quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock worth $10,997,000 after buying an additional 500,900 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Stock Performance

Personalis stock opened at $10.36 on Tuesday. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50. The firm’s 50-day simple moving average is $9.11 and its 200 day simple moving average is $7.50. The stock has a market cap of $919.97 million, a PE ratio of -11.77 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The firm had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. As a group, analysts predict that Personalis will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.